Cantor Fitzgerald Assumes Denali Therapeutics at Overweight, Lowers Price Target of $35
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has assumed coverage of Denali Therapeutics (NASDAQ:DNLI) with an Overweight rating, but has lowered the price target to $35.
October 24, 2023 | 5:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Denali Therapeutics has been given an Overweight rating by Cantor Fitzgerald, indicating a positive outlook. However, the price target has been lowered to $35.
The Overweight rating by Cantor Fitzgerald suggests that they expect Denali Therapeutics' stock to outperform in the market. However, the lowering of the price target might indicate a tempered expectation of the stock's future performance. This could lead to mixed reactions in the market, but overall, the positive rating is likely to have a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100